ArticleEpidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil2025
Prevalence of polypharmacy use and association with mortality: a cohort study of elderly people in Southern Brazil, 2014-2017.
Article in Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmaceutical services: opportunities and perspectives for generating scientific evidence.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo characterize prevalence of polypharmacy use and its association with mortality in elderly people.
methodsProspective cohort (2014 to 2017), with non-institutionalized individuals aged 60 years or over, living in Pelotas, Rio Grande do Sul, Brazil. Association between polypharmacy and mortality was analyzed using Cox regression. Hazard ratios (HR) and their respective 95% confidence intervals (95%CI) were calculated, following the Cox proportional hazards model. Interaction between age groupand multimorbidity was considered to be statistically significant when p-value<0.100.
resultsResults: Polypharmacy prevalence was 36.1% (95%CI 33.7; 38.6), being higher as age group increased (29.8% in those aged 60-69; 41.3% in those aged 70-79). and 47.8% inthose aged 80 years and over). In the adjusted analysis, risk of mortality was 62% higher among elderly people using polypharmacy (HR 1.62; 95%CI 1.10; 2.39), without interaction between age group (p-value 0.750) and multimorbidity (p-value 0.312). Thesurvival analysis demonstrated that the probability of survival was lower in elderly people using polypharmacy (85.6%).
conclusionPolypharmacy prevalence was found to be higher as age group increased and elderly people using polypharmacy had higher risk of mortality, regardless of age group and presence of multimorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.